Discounted Cash Flow
Lifestance Health Group, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $212.5m | $7.9m | $15.8m | 3.7% | — |
| 2020 | $279.0m (31.3%) | $-42.6m (-641.4%) | $8.7m (-45.0%) | -15.3% (-512.3%) | $-0.70 |
| 2021 | $1.4m (-99.5%) | $-307.2m (-620.6%) | $-6.4m (-173.9%) | -21259.3% (-139032.5%) | $-1.05 (-50.0%) |
| 2022 | $859.5m (59383.9%) | $-215.6m (29.8%) | $44.9m (798.8%) | -25.1% (99.9%) | $-0.61 (41.9%) |
| 2023 | $1.1b (22.8%) | $-186.3m (13.6%) | $-20.7m (-146.1%) | -17.6% (29.6%) | $-0.51 (16.4%) |
| 2024 | $1.3b (18.5%) | $-57.4m (69.2%) | $105.8m (610.8%) | -4.6% (74.0%) | $-0.15 (70.6%) |
| 2025 | $1.4b (13.9%) | $9.7m (116.8%) | $143.3m (35.4%) | 0.7% (114.8%) | $0.03 (120.0%) |
| 2026 | $477.4m (-66.5%) | $-37.6m (-488.7%) | $25.3m (-82.3%) | -7.9% (-1259.7%) | $-0.40 (-1433.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.